Effects of Fenformin On Cell Viability and FGFR2 Expression in PC-3 Human Prostate Cancer Cell Line

Prostat kanseri, erkeklerde kansere bağlı ölümlerin ikinci en sık nedenidir. Kemoterapötiklere direnç gelişmesi nedeniyle prostat kanserini tedavi etmek için yeni ilaçlara ihtiyaç vardır. Fenformin biguanid grubu antidiyabetik bir ilaçtır ve antikanserojen etkileri de vardır. Fibroblast büyüme faktörü reseptörü 2 (FGFR2), hücre proliferasyonunu ve farklılaşmasını destekleyen bir membran reseptörüdür. Çalışmamızda; PC-3 insan prostat kanseri hücrelerinde fenforminin FGFR2 üzerinden etkilerinin araştırılması amaçlandı. Deney grupları; kontrol grubu, 1 mM, 2 mM, 5 mM ve 10 mM fenformin uygulanan gruplar idi. Fenformin uygulamalarından 24 saat sonra WST-1 hücre canlılığı analizi yapıldı, ayrıca FGFR2 için immunositokimyasal boyamadan sonra H-Skoru hesaplandı. İstatistiksel analizler için SPSS programı kullanıldı. WST-1 analizi sonuçlarına göre; kontrol grubu ile 5 mM fenformin grubu, kontrol grubu ile 10 mM fenformin grubu ve 1 mM fenformin grubu ile 10 mM fenformin grubu karşılaştırıldığında hücre canlılığında istatistiksel olarak anlamlı derecede azalma tespit edildi (p<0.05, hepsi için). H-Skoru sonuçlarına göre; kontrol grubu ve 5 mM fenformin grubu, kontrol grubu ile 10 mM fenformin grubu, 1 mM fenformin grubu ile 5 mM fenformin grubu ve 1 mM fenformin grubu ile 10 mM fenformin grubu arasındaki FGFR2 ekspresyonunun azalması istatistiksel olarak anlamlıydı (p<0.05, hepsi için). Çalışmamızda fenformin, doza bağlı olarak PC-3 insan prostat kanseri hücreleri üzerinde FGFR2 ekspresyonunu azaltıcı ve hücre proliferasyonunu inhibe edici etkiler göstermiştir. En etkili dozun 10 mM fenformin olduğu tespit edilmiştir.

[1]  J. Ursini-Siegel,et al.  STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer , 2021, Nature Communications.

[2]  L. Di Marcotullio,et al.  Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module. , 2020, Cell reports.

[3]  M. Rotondi,et al.  The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes , 2019, Oncotarget.

[4]  D. Xiao,et al.  Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth , 2019, Front. Pharmacol..

[5]  D. Xiao,et al.  Anticancer properties of novel pyrazole‐containing biguanide derivatives with activating the adenosine monophosphate‐activated protein kinase signaling pathway , 2019, Archiv der Pharmazie.

[6]  Su-Jae Lee,et al.  Effects of metformin and phenformin on apoptosis and epithelial‐mesenchymal transition in chemoresistant rectal cancer , 2019, Cancer science.

[7]  H. Boulaiz,et al.  Phenformin as an Anticancer Agent: Challenges and Prospects , 2019, International journal of molecular sciences.

[8]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[9]  B. Viollet,et al.  Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation , 2019, Cell reports.

[10]  S. Tjulandin,et al.  Role of FGFR2 amplification in prognosis of patients with ovarian cancer. , 2018, Annals of Oncology.

[11]  Mei Peng,et al.  Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways , 2018, Cancer communications.

[12]  Yajie Yin,et al.  Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer , 2017, Oncotarget.

[13]  Behzad Baradaran,et al.  The Different Mechanisms of Cancer Drug Resistance: A Brief Review , 2017, Advanced pharmaceutical bulletin.

[14]  Amanda B. Parris,et al.  Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway , 2017, Oncotarget.

[15]  D. Giugliano,et al.  Insights into the relationships between diabetes, prediabetes, and cancer , 2017, Endocrine.

[16]  Yun Yu,et al.  Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome-mediated degradation of epidermal growth factor receptor. , 2016, Oncology letters.

[17]  H. Car,et al.  Antidiabetic drugs and risk of cancer , 2015, Pharmacological reports : PR.

[18]  R. Wirtz,et al.  Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms , 2015, Histopathology.

[19]  D. Noonan,et al.  The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells , 2015, International journal of cancer.

[20]  K. Struhl,et al.  Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[21]  Joon Young Choi,et al.  Synergistic Anti-Cancer Effect of Phenformin and Oxamate , 2014, PloS one.

[22]  Dean Y. Li,et al.  Blocking Fibroblast Growth Factor Receptor Signaling Inhibits Tumor Growth, Lymphangiogenesis, and Metastasis , 2012, PloS one.

[23]  A. Thompson,et al.  Phenformin as prophylaxis and therapy in breast cancer xenografts , 2012, British Journal of Cancer.

[24]  W. Oh,et al.  PC3 is a cell line characteristic of prostatic small cell carcinoma , 2011, The Prostate.

[25]  M. Katoh,et al.  FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). , 2009, International journal of molecular medicine.

[26]  S. Ethier,et al.  Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells , 2007, Journal of cellular physiology.

[27]  C. Dickson,et al.  Fibroblast growth factor signaling in tumorigenesis. , 2005, Cytokine & growth factor reviews.

[28]  C. Dickson,et al.  A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning , 2003, Development.

[29]  E. Olson,et al.  Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth , 2003, Development.

[30]  C. Dickson,et al.  Development of the Thymus Requires Signaling Through the Fibroblast Growth Factor Receptor R2-IIIb , 2001, The Journal of Immunology.

[31]  Gary W. Harding,et al.  Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 , 1996, Nature Genetics.

[32]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.

[33]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.